Boehringer Ingelheim GmbH / Bridge Biotherapeutics, Inc.
2019 · Licensing/Option · $1.2B · Terminated
Announcement Sentiment
38
Skeptical
Boehringer Ingelheim entered a global collaboration and license agreement for Bridge Biotherapeutics' Phase 1 autotaxin inhibitor BBT-877 in fibrosing interstitial lung diseases including IPF. Bridge received approximately EUR 45M ($50M) in upfront/near-term payments and is eligible for up to EUR 1.1B+ ($1.18B) in milestones plus tiered up-to-double-digit royalties. Deal terminated in late 2020 after BBT-877 mutagenicity findings.